Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients

References

• ClemonsM, DansonS, HowellA. Tamoxifen (‘ Nolvadex ’): a review. Cancer Treat Rev. 2002;7372(02):165–180. doi:10.1016/S0305-7372(02)00036-1
   Web of Science ®Google Scholar
• DaviesC, PanH, GodwinJ, et al. Long-term eff ects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012;6736(12):1–12. DOI:10.1016/S0140-6736(12)61963-1
   Web of Science ®Google Scholar
• HennigEE, PiatkowskaM, KarczmarskiJ, et al. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. BMC Cancer. 2015;15(1). doi:10.1186/s12885-015-1575-4
   Web of Science ®Google Scholar
• TeunissenSF, RosingH, SchinkelAH, SchellensJHM, BeijnenJH. Bioanalytical methods for determination of tamoxifen and its Phase I metabolites: a review. Anal Chim Acta. 2010;683(1):21–37. doi:10.1016/j.aca.2010.10.00921094378
   PubMed Web of Science ®Google Scholar
• Tré-HardyM, CapronA, AntunesMV, LindenR, WallemacqP. Fast method for simultaneous quantification of tamoxifen and metabolites in dried blood spots using an entry level UPLC–MS/MS system. Clin Biochem. 2016;49(16–17):1295–1298. doi:10.1016/j.clinbiochem.2016.07.01827498307
   PubMed Web of Science ®Google Scholar
• TchuSM, LynchKL. Therapeutic drug monitoring of tamoxifen using LC-MS/MS. In: LangmanL, SnozekC, editors. LC-MS in Drug Analysis. Methods in Molecular Biology (Methods and Protocols). Vol. 902. Totowa, NJ: Humana Press; 2012.
   Google Scholar
• SaladoresP, MürdterT, EcclesD, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15(1):84–94. doi:10.1038/tpj.2014.3425091503
   PubMed Web of Science ®Google Scholar
• TeunissenSF, JagerNGL, RosingH, SchinkelAH, SchellensJHM, BeijnenJH. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879(19):1677–1685. doi:10.1016/j.jchromb.2011.04.011
   Web of Science ®Google Scholar
• MadlenskyL, NatarajanL, TchuS, et al. Tamoxifen metabolite concentration, CYP2D6 genotype and breast cancer outcomes. Clin Pharmacol Ther. 2007;86(3):573–579. doi:10.1109/TMI.2012.2196707
   Web of Science ®Google Scholar
• FoxP, BalleineRL, LeeC, et al. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring - The TADE study. Clin Cancer Res. 2016;22(13):3164–3171. doi:10.1158/1078-0432.CCR-15-147026847054
   PubMed Web of Science ®Google Scholar
• WooHI, LeeSK, KimJ, et al. Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget. 2017;8(59):100296–100311. doi:10.18632/oncotarget.2222029245979
   PubMedGoogle Scholar
• MürdterTE, SchrothW, Bacchus-GerybadzeL, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708–717. doi:10.1038/clpt.2011.2721451508
   PubMed Web of Science ®Google Scholar
• LoveRR, DestaZ, FlockhartD, et al. CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. Springerplus. 2013;2(1):52. doi:10.1186/2193-1801-2-5223476897
   PubMedGoogle Scholar
• SchultinkAH, AlexiX, WerkhovenEV, et al. An antiestrogenic activity score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Res Treat. 2018;161(3):567–574. doi:10.1007/s10549-016-4083-6
   Web of Science ®Google Scholar
• RaeJM, DruryS, HayesDF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452–460. doi:10.1093/jnci/djs12622395643
   PubMed Web of Science ®Google Scholar
• JagerNG, RosingH, SchellensJH, BeijnenJH. Determination of tamoxifen and endoxifen in dried blood spots using LC–MS/MS and the effect of coated DBS cards on recovery and matrix effects. Bioanalysis. 2014;6(22):2999–3009. doi:10.4155/bio.14.15725496254
   PubMed Web of Science ®Google Scholar
• AntunesMV, RaymundoS, de OliveiraV, et al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N -desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots—development, validation and clinical application during breast cancer. Talanta. 2015;132:775–784. doi:10.1016/j.talanta.2014.10.04025476377
   PubMed Web of Science ®Google Scholar
• HarahapY,MaggadaniBP,SitorusTRJ,MulyadiCA,PurwantoDJ.Clinical application of dried blood spot for monitoring studies of tamoxifen, endoxifen, and 4-hydroxytamoxifen in breast cancer patient using liquid chromatography. Int J Appl Pharm. 2019;11:59–63. doi:10.22159/ijap.2019v11i2.30310.
   Google Scholar
• JagerNGL, RosingH, LinnSC, SchellensJHM, BeijnenJH. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Res Treat. 2012;133(2):793–798. doi:10.1007/s10549-012-2000-122388692
   PubMed Web of Science ®Google Scholar
• De KrouS, RosingH, NuijenB, SchellensJHM, BeijnenJH. Fast and adequate liquid chromatography-tandem mass spectrometric determination of z-endoxifen serum levels for therapeutic drug monitoring. Ther Drug Monit. 2017;39(2):132–137. doi:10.1097/FTD.000000000000037228045782
   PubMed Web of Science ®Google Scholar
• BinkhorstL, MathijssenRHJ, Ghobadi Moghaddam-HelmantelIM, et al. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2011;56(5):1016–1023. doi:10.1016/j.jpba.2011.08.00221872414
   PubMed Web of Science ®Google Scholar
• KipAE, KiersKC, RosingH, SchellensJHM, BeijnenJH, DorloTPC. Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples. J Pharm Biomed Anal. 2017;135:160–166. doi:10.1016/j.jpba.2016.12.01228033553
   PubMed Web of Science ®Google Scholar
• KokMGM, FilletM. Volumetric absorptive microsampling: current advances and applications. J Pharm Biomed Anal. 2018;147:288–296. doi:10.1016/j.jpba.2017.07.02928803682
   PubMed Web of Science ®Google Scholar
• DenniffP, SpoonerN. Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis. Anal Chem. 2014;86:8489–8495. doi:10.1021/ac502256225058158
   PubMed Web of Science ®Google Scholar
• SpoonerN, DenniffP, MichielsenL, et al. A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated with blood hematocrit. Bioanalysis. 2015;7(6):653–659. doi:10.4155/bio.14.31025514576
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Bioanalytical Method Validation. London, UK: European Medicines Agency. 2011.
   Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry. Bioanalytical Method Validation. Rockville, MD, USA: US FDA; 2018.
   Google Scholar
• KostiainenR, KauppilaTJ. Effect of eluent on the ionization process in liquid chromatography – mass spectrometry. J Chromatogr A. 2009;1216:685–699. doi:10.1016/j.chroma.2008.08.09518799161
   PubMed Web of Science ®Google Scholar
• GosettiF, MazzuccoE, ZampieriD, GennaroMC. Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry. J Chromatogr A. 2010;1217(25):3929–3937. doi:10.1016/j.chroma.2009.11.06020004403
   PubMed Web of Science ®Google Scholar
• JagerNGL, RosingH, SchellensJHM, BeijnenJH, LinnSC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Res Treat. 2014;137–144. DOI:10.1007/s10549-014-2999-2
   Web of Science ®Google Scholar
• BarginearMF, JaremkoM, PeterI, et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011;90(4):605–611. doi:10.1038/clpt.2011.15321900890
   PubMed Web of Science ®Google Scholar
• KhalajZ, BaratiehZ, NikpourP, et al. Clinical trial: CYP2D6 related dose escalation of tamoxifen in breast cancer patients with Iranian ethnic background resulted in increased concentrations of tamoxifen and its metabolites. Front Pharmacol. 2019;10(May):1–13. DOI:10.3389/fphar.2019.0053030728774
   PubMed Web of Science ®Google Scholar
• LimJSL, ChenXA, SinghO, et al. Impact of CYP2D6, CYP3A5, polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;737–750. doi:10.1111/j.1365-2125.2011.03905.x21480951
   PubMed Web of Science ®Google Scholar